Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21662935 | 0.76 | PDPK1 (0.46) | TLR7PDPK1XDHRETPI4KA | |
| SCHEMBL10517093 | 0.75 | CCNE2 (0.44) | TLR8TLR7TLR9PDPK1XDH | |
| SCHEMBL25776372 | 0.74 | JAK3 (0.50) | TLR8TLR7TLR9PDPK1XDH | |
| SCHEMBL25795310 | 0.73 | PDPK1 (0.43) | PDPK1XDHRETPI4KALRRK2 | |
| SCHEMBL2675945 | 0.73 | PDPK1 (0.43) | PDPK1XDHRETPI4KALRRK2 | |
| SCHEMBL31128144 | 0.73 | PDPK1 (0.43) | PDPK1XDHRETPI4KALRRK2 | |
| SCHEMBL13705860 | 0.73 | XDH (0.52) | PDPK1XDHRETPI4KALRRK2 | |
| SCHEMBL29478852 | 0.73 | PDPK1 (0.43) | PDPK1XDHRETPI4KALRRK2 | |
| SCHEMBL17998677 | 0.73 | PRKCI (0.59) | RETLRRK2AURKACSF1R | |
| Iodide SCHEMBL2674409 | 0.72 | PDPK1 (0.42) | PDPK1XDHRETPI4KALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-11377441-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC | 2021-01-28 | — | — | US | disclosed |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | ARAXES PHARMA LLC (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | TLR8 4840/4885TLR7 4551/4885TLR9 4579/4885 |
| US-11377441-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | TLR8 4840/4885TLR7 4551/4885TLR9 4579/4885 |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | KRAS, NRAS, HRAS | TLR8 4845/4885TLR7 4422/4885TLR9 4536/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | TLR8 3341/4885TLR7 2523/4885TLR9 4059/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | TLR8 4688/4885TLR7 4488/4885TLR9 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.